Name
Myeloid sarcoma
ICD-O-1 Morphology
9930/3: Myeloid sarcoma
Effective
1978 - 1991
ICD-O-2 Morphology
9930/3: Myeloid sarcoma
Effective
1992 - 2000
ICD-O-3 Morphology
9930/3: Myeloid sarcoma
Effective
2001 and later
Reportable
for cases diagnosed
1978 and later
Primary Site(s)
See Module 7
Primary site cannot be bone marrow (C421). Most common sites of involvement: skin, lymph nodes, gastrointestinal tract, bone, soft tissue and testis.
Coding Manual:
Hematopoietic Coding Manual (PDF)
Abstractor Notes
Myeloid sarcoma may occur de novo; it may precede or coincide with AML, or represent acute blastic transformation of myelodysplastic syndromes. Myeloid sarcoma may also be the initial manifestation of relapse in a patient with previously diagnosed AML
If Myeloid Sarcoma occurs simultaneously or after an acute myeloid leukemia, see M3 and Module 5:PH10.
If Myeloid Sarcoma occurs simultaneously or after an acute myeloid leukemia, see M3 and Module 5:PH10.
Diagnostic Confirmation
This histology can be determined by positive histology (including peripheral blood) with or without genetics and/or immunophenotyping. Review the Definitive Diagnostic Methods, Immunophenotyping and Genetics Data sections below, and the instructions in the Hematopoietic Manual for further guidance on assigning Diagnostic confirmation.
Grade
Not Applicable
Module Rule
None
Alternate Names
Chloroma
Extramedullary myeloid tumor
Granulocytic sarcoma
GS
Definition
Myeloid sarcoma is a tumor mass consisting of myeloid blasts, with or without maturation, occurring at an anatomical site other than the bone marrow.
Definitive Diagnostic Methods
Genetic testing
Histologic confirmation
Immunophenotyping
Genetics Data
CBFB amplication
Inv(16)
KMT2A-MLLT3 fusion rearrangement
Loss of 5q
Loss of 16q
Loss of 20q
Monosomy 7
Monosomy 16
NPM1
t(8;21)(q22;q22)
Trisomy 4
Trisomy 8
Trisomy 11
Immunophenotyping
CD33+ (expression/positive)
CD34 +/- (positive/negative)
CD56+ (expression/positive)
CD56- (no expression/negative)
CD68 (KP1 but not PGM1)+ (expression/positive)
CD123+ (expression/positive)
CD303+ (expression/positive)
KIT (CD117)+ (expression/positive)
NPM1
Treatments
Chemotherapy
Radiation therapy
Transformations to
There are no known transformations
Transformations from
There are no known transformations
Same Primaries
Corresponding ICD-9 Codes
205.3 Myeloid sarcoma
Corresponding ICD-10 Codes
C92.3 Myeloid sarcoma
Corresponding ICD-10-CM Codes (U.S. only)
C92.3 Myeloid sarcoma (effective October 01, 2015)
Signs and Symptoms
Easy bruising or bleeding
Fatigue
Fever
Petechiae
Shortness of breath
Weakness
Weight loss or loss of appetite
Diagnostic Exams
Progression and Transformation
None
Epidemiology and Mortality
Age: 56 years median (1 month to 89 years range)
Sex: male predominance
Survival: higher probability or prolonged survival for patients who have allogeneic or autologous BM transplantation
Sources
Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J (Eds):
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (Revised 4th edition)
IARC: Lyon 2017
Section: Acute myeloid leukemia and related precursor neoplasms
Pages: 167-168
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (Revised 4th edition)
IARC: Lyon 2017
Section: Acute myeloid leukemia and related precursor neoplasms
Pages: 167-168
International Classification of Diseases for Oncology, Third Edition, Second Revision. Geneva: World Health Organization, 2020.
Section: ICD-O-3.2 (2020) Morphological Codes
Pages: http://www.iacr.com.fr/index.php?option=com_content&view=category&layout=blog&id=100&Itemid=577
Section: ICD-O-3.2 (2020) Morphological Codes
Pages: http://www.iacr.com.fr/index.php?option=com_content&view=category&layout=blog&id=100&Itemid=577
National Cancer Institute
Section: General Information About Acute Myeloid Leukemia
Pages: https://www.cancer.gov/types/leukemia/hp/adult-aml-treatment-pdq
Section: General Information About Acute Myeloid Leukemia
Pages: https://www.cancer.gov/types/leukemia/hp/adult-aml-treatment-pdq